- Home
- CTMX
as 09-05-2025 4:00pm EST
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 349.6M | IPO Year: | 2015 |
| Target Price: | $5.67 | AVG Volume (30 days): | 4.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.49 | EPS Growth: | 263.20 |
| 52 Week Low/High: | $0.40 - $3.10 | Next Earning Date: | 11-06-2025 |
| Revenue: | $141,100,000 | Revenue Growth: | 18.01% |
| Revenue Growth (this year): | -30.62% | Revenue Growth (next year): | -54.55% |
Stock Insider Trading Activity of CytomX Therapeutics Inc. (CTMX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| McCarthy Sean A. | CTMX | CEO | Jun 13 '25 | Sell | $2.69 | 55,511 | $149,263.53 | 1,089,684 | |
| Ogden Christopher | CTMX | Chief Financial Officer | Jun 13 '25 | Sell | $2.82 | 12,255 | $33,381.43 | 199,385 | |
| BELVIN MARCIA | CTMX | SVP, Chief Scientific Officer | Jun 13 '25 | Sell | $2.69 | 13,884 | $37,334.08 | 272,252 |
Latest CytomX Therapeutics Inc. News
CTMX Breaking Stock News: Dive into CTMX Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 months ago
CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference
GlobeNewswire
4 months ago
CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Melanoma
MT Newswires
4 months ago
HC Wainwright Upgrades CytomX Therapeutics to Buy From Neutral, Price Target is $5
Thomson Reuters StreetEvents
4 months ago
Q1 2025 CytomX Therapeutics Inc Earnings Call
MT Newswires
4 months ago
CytomX Shares Jump After Q1 Beat, 'Positive' Interim Trial Data
MT Newswires
4 months ago
Wedbush Adjusts CytomX Therapeutics Price Target to $6 From $5, Maintains Outperform Rating
MT Newswires
4 months ago
Top Premarket Gainers
Zacks
4 months ago
CytomX Therapeutics (CTMX) Beats Q1 Earnings and Revenue Estimates
Compare CTMX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CTMX CytomX Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.